Phase 1 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have signed a consent form agreeing to take part in the study
• Adults aged 18 or older
• People diagnosed with certain types of B-cell Non-Hodgkin Lymphoma (a cancer of the immune system), including large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, or marginal zone lymphoma, who have already tried at least 2 prior treatments and either tried or were not eligible for a specific type of immune cell therapy called CAR T cell therapy (specific prior treatment requirements differ by lymphoma type — confirm with trial site)
• People diagnosed with certain types of T-cell or NK-cell lymphoma (another group of immune system cancers) who have already received at least one prior treatment — some specific subtypes require two or more prior treatments (confirm with trial site)
• People diagnosed with classical Hodgkin Lymphoma where the cancer cells test positive for a marker called CD45, who have had at least 2 prior treatments including specific therapies, and in most cases a stem cell transplant (confirm with trial site)
• People whose chronic lymphocytic leukaemia (CLL) has transformed into a more aggressive lymphoma (called Richter's Transformation), who have had at least one prior treatment for that transformation or whose disease did not respond to initial treatment
• People whose doctor considers them suitable candidates for a type of stem cell transplant using their own cells
• People who previously had a donor stem cell transplant, provided it was more than 6 months ago, they have no active graft-versus-host disease (a condition where donor cells attack the body), and they are not taking medications to suppress the immune system
• People whose kidneys, liver, and heart are functioning at adequate levels as defined by specific test results (confirm with trial site)
• People whose lungs are functioning adequately, with oxygen levels above 92% on room air and no more than mild breathlessness
• People who are generally well enough to carry out normal daily activities with little or no limitation (as measured by a standard medical scale)

Who may not be able to join:

• People with an active hepatitis B or hepatitis C infection
• People with any active infection that is not under control
• People with serious heart failure classified as Class III or IV (meaning significant limitations on physical activity)
• People with an irregular heartbeat that has not been stable with medication within the two weeks before the doctor confirms eligibility
• People with serious other health conditions that, in the treating doctor's judgement, would make participation unsafe
• People with another cancer whose history or required treatment could interfere with the assessment of this trial's treatment
• People with active graft-versus-host disease (a complication from a prior donor stem cell transplant) that requires treatment
• People who are currently dependent on steroid medications or other immune-suppressing drugs
• People with lymphoma that is currently active in the central nervous system (brain or spinal cord) — people who had this previously but were successfully treated may still be considered eligible
• People whose blood tests show signs of a T-cell cancer circulating in the bloodstream
• People with a known allergy or sensitivity to any of the ingredients in the study treatment, including human serum albumin, DMSO, or Dextran 40
• People with an active autoimmune disease requiring immune-suppressing treatment at or above a certain dose level, or people with autoimmune conditions affecting the nervous system (such as multiple sclerosis)
• People who are pregnant or breastfeeding — people who are able to become pregnant must agree to use an acceptable form of contraception during the trial

Important: Always verify eligibility with the trial site directly before applying.